As SGLT2 inhibitors are now a key component of DKD care, this makes the study less generalizable in the current era but also presents opportunities for further research on the relationship between this therapy, distal tubule biomarkers, and kidney outcomes. This evidence concerns the gene SLC5A2 and diabetic kidney disease.